Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).
Naomi Winick(The University of Texas Southwestern Medical Center), Bruce M. Camitta(Medical College of Wisconsin), Jonathan J. Shuster(Health Outcomes Solutions (United States)), Jeanette Pullen, Eric Larsen(University of Massachusetts Chan Medical School), Meenakshi Devidas(National Institutes of Health), Paul Bowman(Pediatric Oncology Group), Paul L. Martin(Duke University), Michael J. Borowitz(Johns Hopkins University), William L. Carroll(NYU Langone Health), Stephen P. Hunger(Children's Hospital of Philadelphia)
Cited by 9
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k